Azaaromatic Amide Derivatives for EGFR Exon 20 Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs are inadequate in effectively inhibiting EGFR exon 20 insertion mutations and HER2 exon 20 insertion mutations, leading to resistance in non-small cell lung cancer and other cancers, with existing treatments causing adverse reactions and toxicity.
Innovation Solution
Development of azaaromatic amide compounds that selectively inhibit EGFR exon 20 insertion mutations, HER2 exon 20 insertion mutations, and HER4 mutations, reducing wild-type EGFR inhibition to minimize adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EGFR kinase inhibitors (Gefitinib, Erlotinib, Afatinib, Osimertinib) are used to treat EGFR exon 20 insertion mutations, then some level of inhibition is achieved, but the inhibition affinity is significantly reduced leading to treatment resistance
Solution Approach 1:
The patent modifies the chemical structure parameters of EGFR inhibitors by introducing azaaromatic amide derivatives with specific molecular characteristics (Formula I compounds). These structural parameter changes enable the inhibitors to achieve high binding affinity to EGFR exon 20 insertion mutants, overcoming the reduced affinity problem of existing drugs and restoring effective inhibition.
Solution Approach 2:
The invention targets the specific local quality of EGFR exon 20 insertion mutations by designing inhibitors with selective binding properties. The azaaromatic amide derivatives are engineered to recognize and bind preferentially to the mutated EGFR structure while maintaining differential binding characteristics, achieving localized effective inhibition of the mutant form.
2Reliability
If wild-type EGFR is strongly inhibited by existing EGFR targeted drugs, then anticancer efficacy is improved, but adverse reactions (rash and diarrhea) and toxicity increase
Solution Approach 1:
The azaaromatic amide derivatives exhibit local quality in their binding characteristics, showing preferential and high-affinity binding to EGFR exon 20 insertion mutations while demonstrating reduced binding affinity to wild-type EGFR. This selective local action achieves effective inhibition of mutant EGFR with minimized off-target effects on wild-type receptors, thereby reducing adverse reactions.
Solution Approach 2:
The patent converts the previously harmful lack of selectivity into a beneficial feature. By designing inhibitors that specifically target mutant EGFR structures, the invention transforms the general toxicity problem into a selective therapy advantage, where the drug's binding properties are optimized to distinguish between mutant and wild-type receptors, turning potential harm into therapeutic benefit.
3Reliability
If HER2 exon 20 insertion mutations are present, then resistance to known HER2 inhibitors develops, but no effective alternative drugs are currently available
Solution Approach 1:
The azaaromatic amide derivatives demonstrate universality by exhibiting inhibitory activity against multiple targets including EGFR exon 20 insertion mutations, HER2 exon 20 insertion mutations, and HER4. This multi-functional capability provides a universal therapeutic solution for various exon 20 insertion mutations across different erbB family members, addressing the unmet need for alternative drugs in resistant cases.
Data Source
AI summary
The present application relates to azaaromatic amide derivatives for the treatment of cancer. Specifically, the present application relates to a preparation method and use of azaaromatic amide derivatives. The present application relates to azaaromatic amide derivatives and anilino-pyrimidine compounds represented by formula (I), formula (II), formula (III), formula (IV), and formula (V), and pharmaceutically acceptable salts thereof; the compounds or salts thereof can be used to treat or prevent a disease or disorder by regulating certain mutant forms of epidermal growth factor receptors. The present application also relates to a pharmaceutical composition comprising the compounds or salts thereof, and a method for treating various diseases mediated by EGFR, or HER2, or HER4 by using the compounds and salts thereof.